Bill
A 2142
Bill A 2142 allows adults 21+ to grow and use psilocybin for treating mental health issues, establishing a regulated framework for cultivation and distribution.
Bill Number: A 2142
Title: Allows the growth, cultivation, and adult use of psilocybin for the treatment of certain health conditions
Status: Referred to Health
Introduced: January 15, 2025
Classification: Bill
Related Bills: S 5303 (companion)
Bill A 2142 aims to legalize the growth, cultivation, and adult use of psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, for therapeutic purposes. The bill seeks to address various health conditions by allowing adults to access psilocybin in a regulated manner. This legislation reflects a growing interest in the potential mental health benefits of psilocybin, particularly for conditions such as depression, anxiety, PTSD, and substance use disorders.
Legalization of Psilocybin Use: The bill permits adults aged 21 and over to legally grow, cultivate, and use psilocybin for personal use and therapeutic purposes.
Regulatory Framework: The bill proposes the establishment of a regulatory framework to oversee the cultivation and distribution of psilocybin. This includes licensing requirements for growers and distributors to ensure safety and quality control.
Health Conditions Covered: Specific health conditions that may be treated with psilocybin will be outlined, potentially including:
Research and Education: The bill encourages research into the therapeutic effects of psilocybin and mandates educational programs to inform the public about its use and potential benefits.
Adults (21+): The primary beneficiaries of this bill would be adults seeking alternative treatments for mental health conditions.
Healthcare Providers: Mental health professionals may have the opportunity to incorporate psilocybin into treatment plans, pending regulatory guidelines.
Cultivators and Distributors: Individuals and businesses involved in the cultivation and distribution of psilocybin would be impacted by the new licensing and regulatory requirements.
Current Status: As of January 15, 2025, the bill has been referred to the Health Committee for further consideration.
Next Steps: The bill will undergo discussions and potential amendments within the committee before it can proceed to a vote in the legislature.
Bill A 2142 represents a significant shift in the approach to mental health treatment by exploring the therapeutic potential of psilocybin. If passed, it could pave the way for new treatment options for individuals suffering from various mental health conditions, while also establishing a regulated market for psilocybin cultivation and use. The ongoing discussions in the Health Committee will be crucial in shaping the final form of this legislation.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
